
Amanda Ramos, MD, a first-year fellow at the Massachusetts General Hospital in Boston, discusses the future potential of checkpoint inhibition therapy in the treatment of patients with recurrent endometrial cancers.

Your AI-Trained Oncology Knowledge Connection!


Published: May 15th 2018 | Updated: